Literature DB >> 19129942

Asthma worsenings: approaches to prevention and management from the Asthma Worsenings Working Group.

Meyer Balter1, Pierre Ernst, Wade Watson, Harold Kim, Lisa Cicutto, Marie-France Beauchesne, Andrew J Cave, Alan Kaplan, Donna Hogg, Andrew McIvor, Tom Smiley, Michel Rouleau, J Mark FitzGerald.   

Abstract

Most asthma patients prescribed maintenance asthma therapies still experience periods of asthma worsenings characterized by daytime or night-time symptoms, or an increased need for rescue medication. In fact, these episodes are highly prevalent even in patients with well-controlled disease. Published literature suggests that asthma worsenings likely represent a window of opportunity during which patients could intervene early to prevent exacerbations or further deterioration of asthma symptoms. However, current evidence suggests that most patients fail to respond or to self-manage appropriately during these periods.To address the issue of asthma worsenings, an interdisciplinary committee of respirologists, allergists, family physicians, pharmacists and certified asthma educators from across Canada developed a practical definition of asthma worsenings and provided approaches to the prevention and management of these episodes based on current literature. To date, combination inhaled corticosteroid/long-acting beta-agonist therapy, particularly single inhaler maintenance and reliever therapy, appears to be an effective strategy for preventing asthma worsenings and exacerbations. Addressing the potential barriers to appropriate patient self-management of asthma worsenings, such as failure to adequately identify and respond to worsenings, low expectations for controlling asthma, low health literacy and poor patient-health care professional communication, are also critical to the successful prevention and management of these episodes. Finally, an interdisciplinary team approach involving patients and their families, certified asthma educators, primary care physicians, pharmacists and specialists is likely to have the greatest impact on the identification, prevention and management of asthma worsenings.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19129942      PMCID: PMC3486700          DOI: 10.1155/2008/973062

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  84 in total

1.  Characteristics of subjects with a high frequency of emergency visits for asthma.

Authors:  L P Boulet; M Bélanger; P Lajoie
Journal:  Am J Emerg Med       Date:  1996-11       Impact factor: 2.469

2.  Exasperations" of asthma: a qualitative study of patient language about worsening asthma.

Authors:  Stephen D Vincent; Brett G Toelle; Rosalie A Aroni; Christine R Jenkins; Helen K Reddel
Journal:  Med J Aust       Date:  2006-05-01       Impact factor: 7.738

Review 3.  The health economics of asthma and rhinitis. I. Assessing the economic impact.

Authors:  K B Weiss; S D Sullivan
Journal:  J Allergy Clin Immunol       Date:  2001-01       Impact factor: 10.793

4.  Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.

Authors:  Paul M O'Byrne; Hans Bisgaard; Philippe P Godard; Massimo Pistolesi; Mona Palmqvist; Yuanjue Zhu; Tommy Ekström; Eric D Bateman
Journal:  Am J Respir Crit Care Med       Date:  2004-10-22       Impact factor: 21.405

5.  Health-related quality of life in adolescents with wheezing attacks.

Authors:  Ashna D Mohangoo; Harry J de Koning; Resiti T Mangunkusumo; Hein Raat
Journal:  J Adolesc Health       Date:  2007-09-04       Impact factor: 5.012

6.  Self-management of asthma in general practice, asthma control and quality of life: a randomised controlled trial.

Authors:  B P A Thoonen; T R J Schermer; G Van Den Boom; J Molema; H Folgering; R P Akkermans; R Grol; C Van Weel; C P Van Schayck
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

Review 7.  Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma.

Authors:  Elizabeth Miller; Malcolm R Sears; Andrew McIvor; Anna Liovas
Journal:  Can Respir J       Date:  2007 Jul-Aug       Impact factor: 2.409

8.  Drug utilization evaluation identifies costs associated with high use of beta-adrenergic agonists.

Authors:  D A Stempel; J F Durcannin-Robbins; E C Hedblom; R Woolf; L L Sturm; A B Stempl
Journal:  Ann Allergy Asthma Immunol       Date:  1996-02       Impact factor: 6.347

9.  Persistent asthma: disease control, resource utilisation and direct costs.

Authors:  E Van Ganse; L Laforest; G Pietri; J P Boissel; F Gormand; R Ben-Joseph; P Ernst
Journal:  Eur Respir J       Date:  2002-08       Impact factor: 16.671

10.  Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study.

Authors:  Martyn R Partridge; Thys van der Molen; Sven-Erik Myrseth; William W Busse
Journal:  BMC Pulm Med       Date:  2006-06-13       Impact factor: 3.317

View more
  3 in total

Review 1.  Bringing asthma care into the twenty-first century.

Authors:  Kjell Larsson; Hannu Kankaanranta; Christer Janson; Lauri Lehtimäki; Björn Ställberg; Anders Løkke; Kristian Høines; Klaus Roslind; Charlotte Suppli Ulrik
Journal:  NPJ Prim Care Respir Med       Date:  2020-06-05       Impact factor: 2.871

2.  Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET.

Authors:  Mark C Liu; Elisabeth H Bel; Oliver Kornmann; Wendy C Moore; Norihiro Kaneko; Steven G Smith; Neil Martin; Robert G Price; Steven W Yancey; Marc Humbert
Journal:  ERJ Open Res       Date:  2022-01-10

3.  Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study.

Authors:  Bradley E Chipps; Frank C Albers; Laurence Reilly; Eva Johnsson; Christy Cappelletti; Alberto Papi
Journal:  BMJ Open Respir Res       Date:  2021-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.